MDFI

Across TCGA pan-cancer cohorts, MDFI Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MDFI data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MDFI Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MDFI expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

COAD, BLCA, and PRAD are the cancer types where MDFI Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.194	0.696	.006	15	view →
BLCA	DFS	Median	All	0.139	0.626	.010	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	All	0.725	0.330	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MDFI–COAD (DFS)

Open the COAD breakdown →